Alerta

ペプチジルグリシンα－アミド化モノオキシゲナーゼ（ＰＡＭ）の測定法及び診断目的のためのその使用

Resumen de: JP2026510789A

本発明は、ＰＡＭの立体構造エピトープに対する少なくとも１つの結合剤を含むアッセイを使用して、体液又は組織試料中のＰＡＭ及び／又はそのアイソフォーム及び／又はその断片のレベルを決定するための方法、並びに診断目的のためのその使用を対象とする。【選択図】なし

改良された血液診断

Resumen de: WO2024200207A1

A method to quantify the abundance of Neurofilament light chain (NFL) in a blood sample, comprising the steps of adding a composition comprising a polyanionic molecule and of reacting it with at least one antibody coupled to a detection system, specifically binding to one epitope of the NFL, its use for a diagnostic application and the corresponding diagnostic kit.

血浆中NEV/OEV的荧光值在辅助鉴别帕金森病和多系统萎缩中的应用

Resumen de: CN121831157A

0001 本发明涉及血浆中NEV/OEV的荧光值在辅助鉴别帕金森病和多系统萎缩中的应用。包括以下步骤：以NEV/OEV作为辅助鉴别PD和MSA的诊断指标，其中，NEV为RT‑QuIC实验中得到NEV反应终点荧光信号最大值，OEV为RT‑QuIC实验中得到OEV反应终点荧光信号最大值。与现有技术相比，本发明首次使用外周血结合α‑syn扩增技术来鉴别鉴别PD和MSA，实现PD与MSA的高效鉴别，填补了外周血中外泌体结合α‑syn扩增技术鉴别两种疾病的空白。

特发性常压脑积水生物标志物、诊断试剂盒及应用

Resumen de: CN121831168A

本发明公开了特发性常压脑积水生物标志物、诊断试剂盒及应用，属于生物医药技术领域，尤其涉及一种特发性常压脑积水生物标志物，所述生物标志物为蛋白质生物标志物，包括NBL1、TREM2、COL3A1、DPP7、PLA1A、SELENBP1、FGB、CCK、WFIKKN2、KNG1、HBA2、GFRA3、CSF1。特发性常压脑积水生物标志物在制备特发性常压脑积水诊断试剂盒中的应用。本发明通过DIA技术筛选差异蛋白，PRM技术验证蛋白表达，筛选得到了特发性常压脑积水生物标志物，用于iNPH的早期筛查、风险评估和预后判断，实现了对iNPH的早期、准确、客观诊断，缩短临床诊断周期，提升诊疗效率。

LRP1-β链短肽作为靶标在治疗主动脉夹层中的应用

Resumen de: CN121818897A

本发明公开了编码LRP1‑β链短肽的基因作为靶标在筛选/制备治疗主动脉夹层的药物中的应用，诱导LRP1‑β链短肽过表达的试剂在制备治疗主动脉夹层的药物中的应用，以及LRP1‑β链短肽作为生物标志物在制备主动脉夹层诊断试剂中的应用。通过实验首次证明了LRP1‑β链短肽可通过下调OPN的表达抑制血管平滑肌细胞表型转化和巨噬细胞炎症浸润，减轻炎症反应，可缓解或抑制主动脉夹层发生发展，为主动脉夹层的治疗提供了新的方向和思路，有望应用在治疗主动脉夹层的新药研发中。

一种基于血浆神经元来源外泌体在抑郁症诊断中的应用

Resumen de: CN121831145A

本发明公开了一种基于血浆神经元来源外泌体在抑郁症诊断中的应用，利用血浆提取神经元来源外泌体检测血清中的 NDEVs 并检测 USP11水平，发现抑郁症患者的 NDEVs 中 USP11 显著高于健康对照，因此血清中的 NDEVs中 USP11水平可以反映颅内神经细胞状态的生物状态，该检测在抑郁症的诊断中能够显著提高检测特异性和敏感度，具有很高的临床应用价值。

基于梯度核酸编码和毛细管电泳的多组学联检方法和进行该方法的系统

Resumen de: CN121831127A

本申请公开了基于梯度核酸编码和毛细管电泳的多组学联检方法和进行该方法的系统。基于梯度核酸编码和毛细管电泳的多组学联检方法包括以下步骤：设计长度和序列均不相同的多个寡核苷酸对；制备标记探针对；反应杂交形成寡核苷酸对；生成对应于待测物的DNA模板；产生带有标记物的、长度各异的DNA扩增产物；制备毛细管电泳谱图；鉴定出对应的待测物种类；和/或，对相应的待测物进行定量分析。该方法在临床诊断、生物标志物发现、蛋白质、基因和代谢组学等生命科学研究中具有广泛的应用前景。

インフラマソーム関連疾患又は病態を処置するための組成物及び方法

Resumen de: JP2026062733A

【課題】炎症性疾患の診断を支援可能なバイオマーカーとその使用方法。【解決手段】多発性硬化症、脳卒中、軽度認知障害、アルツハイマー病、加齢性黄斑変性、ＮＡＳＨ、炎症性老化又は外傷性脳損傷などのインフラマソーム関連疾患又は障害のマーカーとして、対象からのサンプル中のインフラマソームの成分を検出するための組成物及び方法。多発性硬化症、脳卒中、軽度認知障害、アルツハイマー病、加齢性黄斑変性、ＮＡＳＨ、炎症性老化又は外傷性脳損傷などのインフラマソーム関連疾患又は障害を有する対象について、予後を判定し、処置を指示し、且つ処置に対する反応をモニタリングするためにかかるインフラマソームマーカーを使用する方法も記載される。【選択図】図３２

SMAGP FUSION MOLECULES AND METHODS OF USE THEREOF

Resumen de: US20260098070A1

0000 Provided herein are fusion molecules comprising a SMAGP extracellular domain that can modulate leukocyte activity. Also provided are polynucleotides, vectors, and host cells encoding these fusion molecules, and methods of making and using these fusion molecules.

INFLAMMATORY DISEASE GENE PANEL

Resumen de: US20260098305A1

Provided is a method of determining whether a patient has bladder cancer, colon cancer, or breast cancer. Also provided is a method of determining whether a patient has a chronic inflammatory disease. Additionally provided is a method of evaluating patient response to a treatment for a chronic inflammatory disease. Further provided is a method of developing a treatment for a chronic inflammatory disease in a patient.

TREATED DRIED BLOOD SAMPLE FOR DETECTION OF HEAVY METALS IN DRIED BLOOD

Resumen de: US20260098855A1

0000 The present invention provides methods, compositions, kits, and devices for detecting heavy metals in dried blood (e.g., dried blood spots). For example, the present invention provides: 1) dried blood spot paper that is detectably free of heavy metals and methods of preparing such paper using organic acid; 2) dried blood extraction solutions optimized for heavy metal detection (e.g., extraction solutions containing acetic acid and/or gold); 3) methods for estimating venous blood volume from dried blood mass; and 4) kits and kit components optimized for heavy metal detection in dried blood (e.g., kits with paper detectably free of heavy metals, heavy metal free skin wipes, metal free collection case, etc.).

METHODS FOR INHIBITING DIAZEPAM BINDING PROTEIN

Resumen de: US20260097094A1

0000 Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets. Accordingly, the present invention relates to methods and pharmaceutical compositions for modulating autophagy based on the modulation of the activity or expression of DBI.

A MODIFIED PROTEIN SCAFFOLD AND USE THEREOF

Resumen de: US20260098080A1

0000 A protein comprising amino acid sequence of SEQ ID NO: 115, within which a segment of general formula Ih-mod GX<1>CX<1V>X<2>X<3>X<4>X<5 >is present where X<1 >is any of F, Y, L, P, Q, M, V, W, A, or T, X<1V >is R, or K, X<2 >is any of A, G, S, or T, X<3 >is any amino acid of the 17-set, where the 17-set comprises A, I, L, F, or Y, X<4 >is any of K, I, Q, R, H, S, F, M, N, L, or V, and X<5 >is any of R, V, I, K, M, Q, E, F, L, N, Y, D, S, H; and b) in position 34 of SEQ ID NO: 115 it contains an amino acid selected from the 34-set contains any amino acid of the 34-set, where the 34-set comprises Y, I, F, G, V and S, and use in pharmaceutical preparations, kits, screening procedures.

METHOD OF DETERMINING THE HEALTH STATUS OF A DOG

Resumen de: AU2024370445A1

The present invention provides a method for determining a biological age, mortality risk and/or probability of a healthy lifespan of a dog; said method comprising: a) determining a biological age, mortality risk and/or probability of a healthy lifespan of the dog using the level of one or more biomarker(s) in one or more samples obtained from the dog, wherein the one or more biomarker(s) is selected from white blood cell count, serum albumin, serum alkaline phosphatase, serum creatine kinase, haemoglobin, haematocrit, mean corpuscular haemoglobin, serum glucose, mean red cell volume, serum globulin, serum calcium, platelet count, and/or red blood cell count; and b) determining a biological age, mortality risk and/or probability of a healthy lifespan for the dog using a DNA methylation profile from the dog.

A METHOD FOR CLASSIFYING A SUBJECT AS HIGH-RISK FOR NEUROLOGICAL OR PSYCHIATRIC DISORDER

Resumen de: WO2026074061A1

In the present invention provided is a method for classifying a subject as a high-risk for neurological or psychiatric disorder subject. The method is particularly useful when the neurological or psychiatric disorder is selected from the group containing schizophrenia, psychosis, mood disorder, depression (such as major depressive disorder), bipolar disorder, Alzheimer's disease, Parkinson disorder, and cognitive impairment. The present invention further relates to a biomarker kit comprising reagents for determining expression level of biomarkers for extracellular vesicles, brain-derived extracellular vesicles and biomarkers for mitochondrial and redox impairment, N-methyl-D-aspartate receptor pathway, and other pathways related to central nervous system disorders.

COMPOSITIONS AND METHODS FOR MODULATING NEURAL ACTIVITY

Resumen de: WO2026076419A1

Provided herein are, inter alia, methods and compositions for transfecting a brain cell (e.g., neuron). The methods for transfecting a brain cell provided herein including embodiments thereof include, for example, transfecting the brain cell with a viral vector encoding a potassium-selective light-sensitive protein (e.g., kalium channelrhodopsin). Also provided herein are, inter alia, methods of modulating a neural network of brain cells (e.g., neurons) by activating a potassium-selective channelrhodopsin with light. The methods and compositions provided herein are, inter alia, useful for treating neurological or psychiatric diseases or disorders (e.g., epilepsies, Parkinson's disease, Alzheimer's, etc.).

BIOMARKERS IN LONG-COVID-19

Resumen de: US20260098868A1

A method of diagnosing long-COVID-19 in a patient, the method comprising: (a) obtaining a test sample from the patient, (b) performing one or more assays configured to detect a level of one or more biomarkers in the test sample, (c) comparing the level of the one or more proteins in the test sample with a healthy control reference value of said one or more proteins, wherein a change in the level of the one or more biomarkers in the test sample relative to the healthy control reference value of said one or more proteins is indicative of long-COVID-19 diagnosis, wherein the one or more proteins are selected from Table 3.

NON-INVASIVE METHOD FOR DETERMINING RESPIRATORY GASES COMPRISING HYDROGEN SULPHIDE

Resumen de: EP4721657A1

Die vorliegende Erfindung betrifft ein nicht-invasives Verfahren zur Bestimmung von Atemgasen aufweisend Schwefelwasserstoff, insbesondere zur Verwendung in der Medizin, Diagnose, Prädiktion, Risikostratifizierung und Therapiesteuerung von Erkrankungen, insbesondere Darmerkrankungen an Probanden, wobei durch Bakterien gebildete Gase in dem Ausatemgas bestimmt werden, wobei der Schwefelwasserstoff nicht nachteilig abgebaut wird.

预防和治疗阿尔茨海默病药物、靶点、药物筛选方法

Resumen de: CN121796373A

本发明属于生物医药领域，具体的，本发明涉及了预防和治疗阿尔茨海默病药物、靶点、药物筛选方法。本发明揭示了甲状腺激素T4在治疗神经病变中核心靶标蛋白碘化PP2A的作用，为开发预防和治疗神经退行相关疾病的新药物、监测相关药物治疗效果提供了技术基础。甲状腺激素T4可以作为改善受试者记忆与认知功能的药物；补充甲状腺激素T4还可以用于预防和治疗神经退行性相关疾病，为甲状腺激素T4提供了一种全新的医药用途。

一种复合蛋白及其制备方法和应用

Resumen de: CN121800903A

本发明公开了一种复合蛋白及其制备方法和应用，涉及生物领域。本发明开发了一种多磷酸化tau复合蛋白，其包括链霉亲和素以及与所述链霉亲和素相连的抗原A‑生物素A和抗原B‑生物素B，解决现有校准品与天然抗原表位的差异引发试剂批间差过大的问题，校准性能突破性提升，可适配化学发光、酶联免疫等多种检测平台，通用性强，具有重要的临床价值与行业意义。

一种基于RT-QuIC技术的帕金森病辅助诊断试剂盒及其应用

Resumen de: CN121805593A

0001 本发明提供一种基于RT‑QuIC技术的帕金森病辅助诊断试剂盒及其应用，属于检测试剂盒技术领域。本发明提供的试剂盒具有显著的微创性与高患者依从性，仅需采集微量皮肤组织即可完成检测，避免了腰椎穿刺或脑组织活检的风险与痛苦。该试剂盒检测性能优异，能够实现对帕金森病早期病理的高度敏感与特异的识别，且检测流程快捷，可在较短时间内完成批量样本分析，有力支持临床的快速诊断与筛查需求。同时，其整体成本显著低于影像学等现有方法，为帕金森病的早期发现、临床辅助诊断及治疗效果观察提供了便捷、可靠且经济的分子检测手段，对提升该类神经退行性疾病的整体诊疗水平具有积极意义。

基于氮化硅纳米孔和深度学习的生物标志蛋白检测系统

Resumen de: CN121805567A

0001 本发明公开了基于氮化硅纳米孔和深度学习的生物标志蛋白检测系统，涉及纳米孔蛋白检测技术领域，包括基于电导‑孔径公式计算实现孔径的控制；保留并表征结构蛋白在过孔过程中产生的电信号差异；完成生物标志蛋白检测。本发明实现了对结构高度相似的β‑淀粉样蛋白40与β‑淀粉样蛋白42的高精度、高稳定性区分；提升了分类准确率，整体方案兼具工艺可控性、信号解析深度与模型识别能力，为阿尔茨海默病等神经退行性疾病的早期诊断提供了可靠、可产业化的单分子检测技术路径。

用于主动脉夹层检测的生物标志物及其应用

Resumen de: CN121802031A

0001 本发明公开了用于主动脉夹层检测的生物标志物及其应用，所述生物标志物为MDK、NTN1、CCL21、LIPC、DNASE1L3、TFPI2、CTSG、HAMP、CXCL14、PLA2G2A、SCUBE1、GZMK、HP1BP3、SRP14、TOP1中的一种或多种。所述生物标志物通过血浆蛋白组学对主动脉夹层患者血浆筛选而出，表现出较高的敏感性和特异性。本发明通过ELISA验证证明了所述生物标志物可作为主动脉夹层早期诊断性生物标志物，还可以作为评估AD患者疾病严重程度的指标之一，这为主动脉夹层临床早期诊断和远期预后评估，提供了新的方向。

检测MAPT蛋白S202和T205位点磷酸化水平的试剂在制备肾脏纤维化诊断产品中的应用

Resumen de: CN121805597A

0001 本发明公开检测MAPT蛋白S202和T205位点磷酸化水平的试剂在制备肾脏纤维化诊断产品中的应用，本发明首次将MAPT蛋白的功能研究从传统的肾小球足细胞领域拓展至肾小管上皮细胞及其纤维化病理过程，开辟了MAPT蛋白在肾脏疾病研究中的全新方向。不同于既往仅依赖整体基因敲除或过表达的笼统性研究手段，本发明利用位点特异性突变体实现了对MAPT关键磷酸化位点功能的精准解析。通过系统性功能判定实验，本发明揭示了一项具有重大理论意义的反直觉生物学规律：尽管S202和T205位点磷酸化显著驱动肾小管上皮细胞纤维化进程，但模拟该位点去磷酸化状态（S202A/T205A突变体）却无法改善纤维化表型。

ＹａｘＡＢナノポア、それを含むナノポアシステム、およびその活用

Nº publicación: JP2026510435A 06/04/2026

Solicitante:

コリアリサーチインスティテュートオブバイオサイエンスアンドバイオテクノロジー

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.